A cardiovascularis kórképek gyógyításában elért eredmények ellenére a szív-ér rendszeri megbetegedések gyakorisága a fejlett és fejlődő világban növekszik. Ez a tény összefügg a világméretű elhízás-, illetve diabetespandémiával, valamint az úgynevezett urbanizált életforma térhódításával. A szerzők ismertetik a civilizációs életforma és a krónikus stressz összefüggését, valamint a következményes életforma-változások, szív-ér rendszeri kockázatnövekedés érveit. Továbbá megfogalmazzák a cardiovascularis kockázatcsökkentés mai gyakorlatának (polipill-alkalmazás, úgynevezett célértékek elérése) kritikáját. Hangsúlyozzák a cardiovascularis kockázati tényezők következményes természetét, ebből adódóan a kockázati faktor csökkentésére irányuló kezelés mérsékelt hatásfokát. Kiemelik az oki kezelés (életmód-intervenciók, krónikus stresszkezelés) elvi elsőbbrendűségét a gyógyszeres intervenciókkal szemben. Tárgyalják a macroangiopathia és a microangiopathia patogenezisének azonos és eltérő jegyeit. Ismertetik a krónikus stressz szerepét a diabetes kialakulásában, valamint a krónikus stressz létrejöttének kiváltó okait. Tárgyalják a metabolikus szindróma, a 2-es típusú diabetes hátterében levő anyagcserezavar (diszmetabolizmus) létét támogató experimentális és klinikai adatokat, hangsúlyozzák a nem ischaemiás diabeteses cardiomyopathia önálló cardiovascularis kockázati faktorának szerepét. Részletezik a diabeteses cardiovascularis kockázatcsökkentés lehetőségeit: hangsúlyozzák a magas vérnyomás, a hyperlipidaemia csökkentésének hatékonyságát szemben a vércukorcsökkentés mérsékeltebb hatásosságával. Hangsúlyozzák, hogy a fokozott diabeteses cardiovascularis kockázat megszüntetése csak az alapokot képező anyagcserezavar (diszmetabolizmus) ismerete és kezelése által lehetséges. Ismertetik az úgynevezett metabólikus promóterekkel elért eredményeket. Orv. Hetil., 2011, 152, 1353–1361.
Fuster, V., Voute, J.: The neglected epidemic of chronic disease. Lancet, 2005, 366, 1512–1514.
Voute J. , 'The neglected epidemic of chronic disease ' (2005 ) 366 Lancet : 1512 -1514.
Yusuf, S., Hawken, S., Ounpuu, S. és mtsai: Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet, 2004, 364, 937–952.
Ounpuu S. , 'Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study ' (2004 ) 364 Lancet : 937 -952.
Mokdad, A. H., Ford, E. S., Bowman, B. A. és mtsai: Diabetes trends in the U.S.: 1990–1998. Diabet. Care, 2000, 23, 1278–1283.
Bowman B. A. , 'Diabetes trends in the U.S.: 1990–1998 ' (2000 ) 23 Diabet. Care : 1278 -1283.
Yusuf, S., Hawken, S., Ounpuu, S. és mtsai: Obesity and the risk of myocardial infarction in 27 000 participants from 52 countries: a case-control study. Lancet, 2005, 366, 1640–1649.
Ounpuu S. , 'Obesity and the risk of myocardial infarction in 27 000 participants from 52 countries: a case-control study ' (2005 ) 366 Lancet : 1640 -1649.
Yoon, K. H., Lee, J. H., Kim, J-W. és mtsai: Epidemic obesity and type 2 diabetes in Asia. Lancet, 2006, 368, 1681–1688.
Kim J-W. , 'Epidemic obesity and type 2 diabetes in Asia ' (2006 ) 368 Lancet : 1681 -1688.
Ji, C. Y., Cheng, T. O.: Epidemic increase in overweight and obesity in Chinese children from 1985 to 2005. Int. J. Cardiol., 2009, 132, 1–10.
Cheng T. O. , 'Epidemic increase in overweight and obesity in Chinese children from 1985 to 2005 ' (2009 ) 132 Int. J. Cardiol. : 1 -10.
Dressler, W. W.: Modernization, stress, and blood pressure: New directions in research. Hum. Biol., 1999, 71, 583–605.
Dressler W. W. , 'Modernization, stress, and blood pressure: New directions in research ' (1999 ) 71 Hum. Biol. : 583 -605.
De Kloet, E. R., Joëls, M., Holsboer, F.: Stress and the brain: from adaptation to disease. Nat. Rev. Neurosci., 2005, 6, 463–475.
Holsboer F. , 'Stress and the brain: from adaptation to disease ' (2005 ) 6 Nat. Rev. Neurosci. : 463 -475.
McEwen, B. S., Seeman, T.: Protective and damaging effects of mediators of stress: Elaborating and testing the concepts of allostasis and allostatic load. Ann. NY Acad. Sci., 1999, 896, 30–47.
Seeman T. , 'Protective and damaging effects of mediators of stress: Elaborating and testing the concepts of allostasis and allostatic load ' (1999 ) 896 Ann. NY Acad. Sci. : 30 -47.
Douglas, L. M.: Stress-activated cytokines and the heart: From adaptation to maladaptation. Ann. Rev. Physiol., 2003, 65, 81–101.
Douglas L. M. , 'Stress-activated cytokines and the heart: From adaptation to maladaptation ' (2003 ) 65 Ann. Rev. Physiol. : 81 -101.
Selye, H.: A syndrome produced by diverse nocuous agents. Nature, 1936, 138, 32–45.
Selye H. , 'A syndrome produced by diverse nocuous agents ' (1936 ) 138 Nature : 32 -45.
Adam, T. C., Epel, E. S.: Stress, eating and the reward system. Physiol. Behav., 2007, 91, 449–458.
Epel E. S. , 'Stress, eating and the reward system ' (2007 ) 91 Physiol. Behav. : 449 -458.
Kassiotis, C., Rajabi, M., Taegtmeyer, H.: Metabolic reserve of the heart: The forgotten link between contraction and coronary flow. Prog. Cardiovasc. Dis., 2008, 51, 74–88.
Taegtmeyer H. , 'Metabolic reserve of the heart: The forgotten link between contraction and coronary flow ' (2008 ) 51 Prog. Cardiovasc. Dis. : 74 -88.
Dallman, M. F., Pecoraro, N. C., la Fleur, S. E.: Chronic stress and comfort foods: Selfmedication and abdominal obesity. Brain Behav. Immun., 2005, 19, 275–280.
Fleur S. E. , 'Chronic stress and comfort foods: Selfmedication and abdominal obesity ' (2005 ) 19 Brain Behav. Immun. : 275 -280.
Gluckman, P. D., Hanson, M. A., Cooper, C. és mtsa: Effect of in utero and early-life conditions on adult health and disease. N. Engl. J. Med., 2008, 359, 61–63.
Cooper C. , 'Effect of in utero and early-life conditions on adult health and disease ' (2008 ) 359 N. Engl. J. Med. : 61 -63.
Varman, T. S., Kitt, F. P., Sulman, G. I.: Lipid-induced insulin resistance: unravelling the mechanism. Lancet, 2010, 375, 2267–2277.
Sulman G. I. , 'Lipid-induced insulin resistance: unravelling the mechanism ' (2010 ) 375 Lancet : 2267 -2277.
Kopp, M. S., Réthelyi, J.: Where psychology meets physiology: chronic stress and premature mortality – the Central-Eastern European health paradox. Brain Res. Bull., 2004, 62, 351–367.
Réthelyi J. , 'Where psychology meets physiology: chronic stress and premature mortality – the Central-Eastern European health paradox ' (2004 ) 62 Brain Res. Bull. : 351 -367.
Taegtmeyer, H.: Cardiac metabolism as a target for the treatment of heart failure. Circulation, 2004, 110, 894–896.
Taegtmeyer H. , 'Cardiac metabolism as a target for the treatment of heart failure ' (2004 ) 110 Circulation : 894 -896.
Silke, B.: Beta-blockade in CHF: pathophysiological considerations. Eur. Heart J., 2006, Suppl. 8 (Suppl. C), C13–18.
Silke B. , 'Beta-blockade in CHF: pathophysiological considerations ' (2006 ) Suppl. 8 (Suppl. C) Eur. Heart J. : C13 -18.
Essop, M. F., Opie, L. H.: Metabolic therapy for heart failure. Eur. Heart J., 2004, 25, 1765–1768.
Opie L. H. , 'Metabolic therapy for heart failure ' (2004 ) 25 Eur. Heart J. : 1765 -1768.
Ceriello, A., Ihnat, M. A., Thorpe, J.: The „metabolic memory”: Is more than just tight glucose control necessary to prevent diabetic complications? J. Clin. Endocrinol. Metab., 2009, 94, 410–415.
Thorpe J. , 'The „metabolic memory”: Is more than just tight glucose control necessary to prevent diabetic complications? ' (2009 ) 94 J. Clin. Endocrinol. Metab. : 410 -415.
Reaven, G.: Insulin resistance, type 2 diabetes mellitus, and cardiovascular disease. The end of the beginning. Circulation, 2005, 112, 3030–3032.
Reaven G. , 'Insulin resistance, type 2 diabetes mellitus, and cardiovascular disease. The end of the beginning ' (2005 ) 112 Circulation : 3030 -3032.
Haffner, S. M.: Abdominal obesity, insulin resistance, and cardiovascular risk in pre-diabetes and type 2 diabetes. Eur. Heart J., 2006, Suppl. 8 (Suppl. B), B20–25.
Haffner S. M. , 'Abdominal obesity, insulin resistance, and cardiovascular risk in pre-diabetes and type 2 diabetes ' (2006 ) Suppl. 8 (Suppl. B) Eur. Heart J. : B20 -25.
Eckel, R. H., Grundy, S. M., Zimmet, P.: The metabolic syndrome. Lancet, 2005, 365, 1415–1428.
Zimmet P. , 'The metabolic syndrome ' (2005 ) 365 Lancet : 1415 -1428.
Mozzaffarian, D., Wilson, P. W. F., Kannel, W. B.: Beyond established and novel risk factors. Lifestyle risk factors for cardiovascular disease. Circulation, 2008, 117, 3031–3038.
Kannel W. B. , 'Beyond established and novel risk factors. Lifestyle risk factors for cardiovascular disease ' (2008 ) 117 Circulation : 3031 -3038.
Dluhy, R. G., McMahon, G. T.: Intensive glycemic control in the ACCORD and ADVANCE trials. N. Engl. J. Med., 2008, 358, 2630–2633.
McMahon G. T. , 'Intensive glycemic control in the ACCORD and ADVANCE trials ' (2008 ) 358 N. Engl. J. Med. : 2630 -2633.
Krumholz, H. M., Lee, T. H.: Redefining quality – Implications of recent clinical trials. N. Engl. J. Med., 2008, 358, 2537–2539.
Lee T. H. , 'Redefining quality – Implications of recent clinical trials ' (2008 ) 358 N. Engl. J. Med. : 2537 -2539.
Montori, V. M., Gandhy, G. Y., Guyatt, G. H.: Patient-important outcomes in diabetes – time for consensus. Lancet, 2007, 370, 1104–1106.
Guyatt G. H. , 'Patient-important outcomes in diabetes – time for consensus ' (2007 ) 370 Lancet : 1104 -1106.
Bell, D. S. H.: Advantages of a third-generation ß-blocker in patients with diabetes mellitus. Am. J. Cardiol., 2004, 93 (9A), 49B–52B.
Bell D. S. H. , 'Advantages of a third-generation ß-blocker in patients with diabetes mellitus ' (2004 ) 93 Am. J. Cardiol. : 49B -52B.
Simon K.: Civilizációs stressz – cardiovascularis kockázat – evidence based medicine – guideline-ok. Orv. Hetil., 2009, 150, 895–902.
Simon K. , 'Civilizációs stressz – cardiovascularis kockázat – evidence based medicine – guideline-ok ' (2009 ) 150 Orv. Hetil. : 895 -902.
Goldberg, R. B.: Lifestyle interventions to prevent type 2 diabetes. Lancet, 2006, 368, 1634–1636.
Goldberg R. B. , 'Lifestyle interventions to prevent type 2 diabetes ' (2006 ) 368 Lancet : 1634 -1636.
Sinclair, K. D., Allegrucci, C., Singh, R. és mtsai: DNA methylation, insulin resistance, and blood pressure in offspring determined by maternal periconceptional B vitamin and methionine status. Proc. Natl. Acad. Sci., 2007, 104, 19351–19356.
Singh R. , 'DNA methylation, insulin resistance, and blood pressure in offspring determined by maternal periconceptional B vitamin and methionine status ' (2007 ) 104 Proc. Natl. Acad. Sci. : 19351 -19356.
Graymore, C. N.: Biochemistry of the retina. In: Biochemistry of the eye. Ed.: Graymore, C. N. London–New York, Academic Press, 1970.
Graymore C. N. , '', in Biochemistry of the eye , (1970 ) -.
Libby, P., Plutzky, J.: Diabetic macrovascular diseases. The glucose paradox? Circulation, 2002, 106, 2760–2763.
Plutzky J. , 'Diabetic macrovascular diseases. The glucose paradox? ' (2002 ) 106 Circulation : 2760 -2763.
DCCT: The relationship of glycemic exposure (HbA1c) to the risk of development and progression of retinopathy in the diabetes control and complications trial. Diabetes, 1995, 44, 968–983.
'The relationship of glycemic exposure (HbA1c) to the risk of development and progression of retinopathy in the diabetes control and complications trial ' (1995 ) 44 Diabetes : 968 -983.
UK Prospective Diabetes Study (UKPDS) Group: Intensive blood-glucose control with suphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet, 1998, 352, 837–853.
'Intensive blood-glucose control with suphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33) ' (1998 ) 352 Lancet : 837 -853.
Ihnat, M. A., Thorpe, J. E., Ceriello, A.: Hypothesis: the “metabolic memory”, the new challenge of diabetes. Diabet. Med., 2007, 24, 582–586.
Ceriello A. , 'Hypothesis: the “metabolic memory”, the new challenge of diabetes ' (2007 ) 24 Diabet. Med. : 582 -586.
Soläng, L., Malmberg, K., Rydén, L.: Diabetes mellitus and congestive heart failure. Eur. Heart J., 1999, 20, 789–795.
Rydén L. , 'Diabetes mellitus and congestive heart failure ' (1999 ) 20 Eur. Heart J. : 789 -795.
Hattersley, A., Tooke J. E.: The fetal insulin hypothesis: an alternative explanation of the association of low birthweight with diabetes and vascular disease. Lancet, 1999, 353, 1789–1792.
Tooke J. E. , 'The fetal insulin hypothesis: an alternative explanation of the association of low birthweight with diabetes and vascular disease ' (1999 ) 353 Lancet : 1789 -1792.
McCarthy, M. I.: Genomics, type 2 diabetes, and obesity. N. Engl. J. Med., 2010, 363, 2339–2350.
McCarthy M. I. , 'Genomics, type 2 diabetes, and obesity ' (2010 ) 363 N. Engl. J. Med. : 2339 -2350.
Guha, A., Harmancey, R., Taegtmeyer, H.: Nonischemic heart failure in diabetes mellitus. Curr. Opin. Cardiol., 2008, 23, 241–248.
Taegtmeyer H. , 'Nonischemic heart failure in diabetes mellitus ' (2008 ) 23 Curr. Opin. Cardiol. : 241 -248.
Varman, T. S., Petersen, K. F., Shulman, G. I.: Lipid-induced insulin resistance: unravelling the mechanism. Lancet, 2010, 375, 2267–2277.
Shulman G. I. , 'Lipid-induced insulin resistance: unravelling the mechanism ' (2010 ) 375 Lancet : 2267 -2277.
Von Bibra, H., St. John Sutton, M.: Diastolic dysfunction in diabetes and the metabolic syndrome: promising potential for diagnosis and prognosis. Diabetologia, 2010, 53, 1033–1045.
John Sutton M. , 'Diastolic dysfunction in diabetes and the metabolic syndrome: promising potential for diagnosis and prognosis ' (2010 ) 53 Diabetologia : 1033 -1045.
Horowitz, J. D., Chirkov, Y. Y., Kennedy, J. A. és mtsa: Modulation of myocardial metabolism: an emerging therapeutic principle. Curr. Opin. Cardiol., 2010, 25, 329–334.
Kennedy J. A. , 'Modulation of myocardial metabolism: an emerging therapeutic principle ' (2010 ) 25 Curr. Opin. Cardiol. : 329 -334.
Woodfield, S. L., Lundergan, C. F., Reiner, J. S. és mtsai: Angiographic findings and outcome in diabetic patients treated with thrombolytic therapy for acute myocardial infarction: the GUSTO-1 experience. J. Am. Coll. Cardiol., 1996, 28, 1661–1669.
Reiner J. S. , 'Angiographic findings and outcome in diabetic patients treated with thrombolytic therapy for acute myocardial infarction: the GUSTO-1 experience ' (1996 ) 28 J. Am. Coll. Cardiol. : 1661 -1669.
Rosano, G. M., Vitale, C., Volterrani, M. és mtsai: Metabolic therapy for the diabetic patients with ischemic heart disease. Coron. Artery Dis., 2005, 16 (Suppl. 1), S17–21.
Volterrani M. , 'Metabolic therapy for the diabetic patients with ischemic heart disease ' (2005 ) 16 Coron. Artery Dis. : S17 -21.
Beckman, J. A., Greager, M. A., Libby, P.: Diabetes and atherosclerosis. Epidemiology, pathophysiology, and management. JAMA, 2002, 287, 2570–2581.
Libby P. , 'Diabetes and atherosclerosis. Epidemiology, pathophysiology, and management ' (2002 ) 287 JAMA : 2570 -2581.
Qiao, Q., Pyörälä, K., Pyörälä, M.: Two-hour glucose is a better risk predictor for incident coronary heart disease and cardiovascular mortality than fasting glucose. Eur. Heart J., 2002, 23, 1267–1275.
Pyörälä M. , 'Two-hour glucose is a better risk predictor for incident coronary heart disease and cardiovascular mortality than fasting glucose ' (2002 ) 23 Eur. Heart J. : 1267 -1275.
Gall, M. A., Borch-Johnsen, K., Hougaard, P. és mtsai: Albuminuria and poor glycemic control predict mortality in NIDDM. Diabetes, 1995, 44, 1303–1309.
Hougaard P. , 'Albuminuria and poor glycemic control predict mortality in NIDDM ' (1995 ) 44 Diabetes : 1303 -1309.
Klein, R.: Hyperglycemia and microvascular and macrovascular disease in diabetes. Diabet. Care, 1995, 18, 258–268.
Klein R. , 'Hyperglycemia and microvascular and macrovascular disease in diabetes ' (1995 ) 18 Diabet. Care : 258 -268.
Hung, K. J., Resendez, R. G., Williams, K. és mtsai: National cholesterol education program versus World Health Organization metabolic syndrome in relation to all-cause and cardiovascular mortality in the San Antonio Heart Study. Circulation, 2004, 110, 1251–1257.
Williams K. , 'National cholesterol education program versus World Health Organization metabolic syndrome in relation to all-cause and cardiovascular mortality in the San Antonio Heart Study ' (2004 ) 110 Circulation : 1251 -1257.
Corrigendum to ’ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008’. Eur. Heart J., 2008, 29, 2388–2442. and Eur. Heart J. Fail., 2008, 10, 933–989.
Morrow, D. A., Givertz M. M.: Modulation of myocardial energetics: emerging evidence for a therapeutic target in cardiovascular disease. Circulation, 2005, 112, 3218–3221.
Givertz M. M. , 'Modulation of myocardial energetics: emerging evidence for a therapeutic target in cardiovascular disease ' (2005 ) 112 Circulation : 3218 -3221.
Anfossi, G., Russo, I., Bonomo, K. és mtsa: The cardiovascular effects of metformin: further reasons to consider an old drug as a cornerstone in the therapy of type 2 diabetes mellitus. Curr. Vasc. Pharmacol., 2010, 8, 328–337.
Bonomo K. , 'The cardiovascular effects of metformin: further reasons to consider an old drug as a cornerstone in the therapy of type 2 diabetes mellitus ' (2010 ) 8 Curr. Vasc. Pharmacol. : 328 -337.
UK Prospective Diabetes Study (UKPDS) Group: Effect of intensive blood-glucose control with metformin on complication in overweight patients with type 2 diabetes (UKPDS 34). Lancet, 1998, 352, 854–865.
'Effect of intensive blood-glucose control with metformin on complication in overweight patients with type 2 diabetes (UKPDS 34) ' (1998 ) 352 Lancet : 854 -865.
De Caterina, R., Madonna, R., Sourij, H. és mtsa: Glycaemic control in acute coronary syndromes: prognostic value and therapeutic options. Eur. Heart J., 2010, 31, 1557–1564.
Sourij H. , 'Glycaemic control in acute coronary syndromes: prognostic value and therapeutic options ' (2010 ) 31 Eur. Heart J. : 1557 -1564.
Heusch, G., Skyschally, A., Gres, P. és mtsai: Improvement of regional myocardial blood flow and function and reduction of infarct size with ivabradine: protection beyond heart rate reduction. Eur. Heart J., 2008, 29, 2265–2275.
Gres P. , 'Improvement of regional myocardial blood flow and function and reduction of infarct size with ivabradine: protection beyond heart rate reduction ' (2008 ) 29 Eur. Heart J. : 2265 -2275.
D’Agostino, R. B. Sr., Grundy, S., Sullivan, L. M. és mtsai: Validation of the Framingham coronary heart disease prediction scores: results of a multiple ethnic groups inverstigation. JAMA, 2001, 286, 180–187.
Sullivan L. M. , 'Validation of the Framingham coronary heart disease prediction scores: results of a multiple ethnic groups inverstigation ' (2001 ) 286 JAMA : 180 -187.